Solid Biosciences Inc
NASDAQ:SLDB

Watchlist Manager
Solid Biosciences Inc Logo
Solid Biosciences Inc
NASDAQ:SLDB
Watchlist
Price: 5.49 USD 3% Market Closed
Market Cap: 427.7m USD

Solid Biosciences Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Solid Biosciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Solid Biosciences Inc
NASDAQ:SLDB
Net Income (Common)
-$167.1m
CAGR 3-Years
-23%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Solid Biosciences Inc
Glance View

Market Cap
427.6m USD
Industry
Biotechnology

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2018-01-26. Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. SGT-001 is its lead gene transfer candidate and utilizes an adeno-associated virus (AAV)9 vector. In addition to its gene transfer candidates, it has development programs focusing on platform technologies, including dual gene expression, a technology that allows it to package multiple transgenes into one vector, as well as capsids. The company is developing SGT-001 for the treatment of Duchenne through a single intravenous administration.

SLDB Intrinsic Value
Not Available

See Also

What is Solid Biosciences Inc's Net Income (Common)?
Net Income (Common)
-167.1m USD

Based on the financial report for Sep 30, 2025, Solid Biosciences Inc's Net Income (Common) amounts to -167.1m USD.

What is Solid Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-11%

Over the last year, the Net Income (Common) growth was -64%. The average annual Net Income (Common) growth rates for Solid Biosciences Inc have been -23% over the past three years , -11% over the past five years .

Back to Top